In this episode of the DeviceTalks Weekly Podcast, host Tom Salemi sits down with Rachel Ellingson, chief strategy and corporate development officer at Solventum, recorded live at DeviceTalks Minnesota. Ellingson shares a rare perspective on leading medical device companies through major transitions, drawing on her experience at Zimmer Biomet during the ZimVie spinout and now at the helm of a business spun out from 3M Healthcare. She compares the two experiences and outlines what’s ahead for Solventum.

In our Future of MedTech Opportunities (FOMO) segment, Kayleen Brown speaks with Athar Mirza, VP of global infusion systems at Baxter International, about Baxter’s evolving role in connected health.

This episode is brought to you by Protolabs, https://www.protolabs.com.

Chris Newmarker and Sean Whooley break down the latest Newmarker’s Newsmakers, featuring headlines from Science, Olympus, Johnson & Johnson, and Stryker. Plus, Whooley shares insights from the American Diabetes Association meeting in Chicago, highlighting cutting-edge diabetes tech.

Thanks for tuning in to the DeviceTalks Weekly Podcast.

Enjoy this podcast? Follow DeviceTalks Weekly all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Join Olympus’ Melissa Elliott-Walker and Dr. Julie Yang as they discuss the vital relationship between Clinical Applications Specialists and HCPs.

Discover the impact of endoscopic ultrasound (EUS) in diagnosing and treating diseases, and learn about the latest advancements in this transformative technology.

ADDITIONAL RESOURCES:

1. Connect with your local CAS. They are ready to support your EUS practice and help you enhance patient care. For more information, visit: info.olympusamericamarketing.com/eus-cas

For more episodes by OlympusTalks, please visit olympusamerica.com/podcasts.

* Dr. Julie Yang is a paid consultant of Olympus Corporation, its subsidiaries, and/or its affiliates. The content of this podcast was paid for by Olympus.

Enjoy this podcast? Follow OlympusTalks on all major podcast players: https://olympustalks.castos.com/subscribe + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode.

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi talks with Paul LaViolette, president and CEO of Pulse Biosciences. LaViolette takes us back to the early days of the medical device industry and shares how close collaboration with interventionalists helped shape today’s MedTech landscape. We dive into one of the biggest deals in MedTech history — Boston Scientific’s acquisition of Guidant — and why it was crucial for the company’s survival despite its rocky road.

LaViolette also explains why investing in MedTech has never been more challenging and what drew him to lead Pulse Biosciences, a company pushing the boundaries of energy-based devices.

Before that, we’re proud to launch our new Future of MedTech Opportunities (FOMO) series, sponsored by Protolabs, https://www.protolabs.com/. In this installment, we speak with Anthony Jarc, vice president of digital and machine learning at Intuitive.

And as always, Chris Newmarker of Newmarker’s Newsmakers rounds up the biggest headlines, covering SS Innovations, Medtronic, Virtual Incision, and highlights from the American Diabetes Association’s annual meeting.

Thanks for tuning in to DeviceTalks Weekly.

Make sure to subscribe to the DeviceTalks Podcast Network so you never miss an episode: https://devicetalks.castos.com/subscribe